Ascletis Pharma Inc.

Investors

Notification Letter to Non-Registered Holders of Shares with Request Form - Notice of Publication of Circular containing Notice of Annual General Meeting
2022-05-24
Notice of 2022 Annual General Meeting
2022-05-24
Form of Proxy for the 2022 Annual General Meeting
2022-05-24
Proposals for General Mandates to Issue Shares and to Repurchase Shares, Re-Election of Retiring Directors, Proposed Amendments to The Memorandum and Articles of Association and Notice of Annual General Meeting
2022-05-24
Proposed Adoption of Amended and Restated Memorandum and Articles of Association
2022-05-19
Voluntary Announcement - Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab) for Immune Restoration/Functional Cure of HIV-1 Infected Patients
2022-05-11
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2022
2022-05-05
Notification Letter with Request Form to Non-Registered Holders of Shares - Notice of Publication of Annual Report 2021
2022-04-20
Annual Report 2021
2022-04-20
Inside Information - Business Update: 3CLpro Inhibitor ASC11 Demonstrated Potential to be Effective Treatment for COVID-19
2022-04-19

1

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1